August 17, 2017
How to Optimize your Non GLP Toxicology Studies
Most new drug candidates fail in the clinic because they are not efficacious or are not safe. Optimizing non-clinical safety studies can save time, money, and animal resources in the long run.
LEARN MORE
August 15, 2017
Genetically Engineered Mouse Models (GEMM) for I/O Studies
Led largely by the growth in immuno-oncology research, older immunocompetent model use continues to rise. These models ...
LEARN MORE
August 10, 2017
Tumor Necrosis Factor Superfamily of Ligands and Receptors 101
Members of the large Tumor Necrosis Factor (TNF) superfamily (TNFSF) of proteins participate in the coordinated ...
LEARN MORE
August 8, 2017
Syngeneic Tumor Mouse Models: The Pros and Cons
Immunotherapeutics are bringing remarkable survival rates for certain cancer patients, but they are also bringing some ...
LEARN MORE
August 3, 2017
How Patient Derived Tumor Grafts (PDX) Accelerate Early Drug Development
× Over the year’s cancer research and drug development have moved from developing “simple” chemotherapies which stop ...
LEARN MORE
August 1, 2017
NASH Drug Development Race Intensifies
There is no FDA-approved treatment for NASH, which affects 3-5% of Americans. Competition to deliver the first ...
LEARN MORE
July 27, 2017
Polycystic Kidney Disease (PKD): The Argument for Multiple Rodent Models
Rodent models of PKD are critical to studying both its molecular basis and progression, but the complexity of Polycystic kidney disease's cellular alterations and signaling pathways make the leap from preclinical studies to approved treatment of human disease almost impossible. The use of multiple animal models in parallel may be the most effective ...
LEARN MORE
July 25, 2017
Precision Medicine: First Multi-Agent Next-Generation Sequencing Companion Diagnostic Test Approved by the FDA
Following our recent blog covering the first US FDA approval for a cancer treatment based on a biomarker regardless of ...
LEARN MORE
July 20, 2017
Overcoming the Tumor Microenvironment and Heterogeneity to Improve Preclinical Response
It is well known that the tumor microenvironment is quite complex to model preclinically. A major challenge we face is ...
LEARN MORE
July 18, 2017
Overcoming Acquired Resistance with PDX
Targeted therapies have been very successful in cancer treatment. Approved for a range of targets across many cancer ...
LEARN MORE
July 18, 2017
How to Use PDX in Immuno-Oncology Studies
Patient-derived xenografts (PDX) are a commonly used preclinical drug development tool, engrafted into immunodeficient mice and used to test the efficacy of novel anticancer agents. It’s widely accepted that these models provide the most predictive preclinical data to inform on clinical trial, as well as offering highly specific patient-relevant mutations, ...
LEARN MORE
July 13, 2017
Progress Towards a Cure for Polycystic Kidney Disease
Polycystic kidney disease (polycystic kidney syndrome, PKD, or PCKD) is a genetic disorder in which numerous abdominal ...
LEARN MORE
July 11, 2017
Oncolytic Viruses: From History to Where We Go Next
One of the more innovative weapons in our anticancer armamentarium has to be oncolytic viruses. Their rationale as an ...
LEARN MORE
July 6, 2017
How Bioluminescent Xenografts Can Progress Preclinical Research
Conventional xenografts are the first step in the in vivo oncology drug discovery process – for early stage research ...
LEARN MORE
June 15, 2017
Why the Current Excitement over Krill in CVD?
Krill are small crustaceans found in all the world's oceans, which have been harvested as a human and animal food ...
LEARN MORE